e12da6001fd64cf38c9e07c84c45a295

New Product Launch: Losartan Tablets

Fri, 23 Sep 2022 12:31:27 GMT

We are pleased to announce the launch of losartan tablets. Product details are as follows:

Pipeline Developments

Mon, 15 Feb 2021 14:05:07 GMT

New partnership to bolster product development

Healthcare Pharma are pleased to announce that they have partnered with JCS Pharma to develop a range of generic products.

Leveraging JCS Pharma's product development expertise, we are focussing on the development of a variety of different pharmaceutical products for various therapeutic areas. For more information about JCS Pharma, visit their website: https://jcspharma.co.uk/

New Product Launch: Azathioprine Tablets

Wed, 20 Jan 2021 20:23:54 GMT

We are pleased to announce the launch of azathioprine tablets. Product details are as below:

New Team Member

Sun, 03 Feb 2019 00:00:00 GMT

We're delighted that Sharon Norcott has joined Healthcare Pharma. Sharon will be managing our sales processing and purchasing functions to support both our customers and suppliers.
Sharon has a wealth of knowledge of the financial sector, her last role being an Accounting Operations Manager. So she is certainly at ease operating within highly regulated environments. We wish her all the best in the new role.

Tender Success

Tue, 29 Jan 2019 00:00:00 GMT

We are delighted to have been successful in the latest round of contracts for supplying NHS hospitals in England with generic medicines.

The NHS National Generic Pharmaceuticals Contact is awarded to companies who are best able to deliver high quality generic medication at competitive prices and in an efficient manner. So this is a real feather in our caps.

Further information about the work of the Commercial Medicines Unit can be found at https://www.gov.uk/government/collections/commercial-medicines-unit-cmu

Ondansetron ODT Granted

Tue, 18 Dec 2018 00:00:00 GMT

The MHRA has approved our licence application for Ondansetron 4mg and 8mg Orodispersible Tablets. The tablets are indicated in adults for

management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy
prevention of post-operative nausea and vomiting(PONV)

In children aged ≥6 months, ondansetron is indicated for the management of chemotherapy-induced nausea and vomiting (CINV).

This is the first Marketing Authorisation submitted under the Healthcare Pharma banner.

Detailed prescribing information is available at www.medicines.org.uk/emc